Divi's Laboratories Limited vs Par Drugs And Chemicals Limited
A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Par Drugs And Chemicals Limited (PAR) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divi's Laboratories Limited leads DIVISLAB vs PAR on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability40
- Growth20
- Size & financial health30
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
PAR takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
DIVISLAB takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
- − ["Stock is trading at 14.48 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
- + ["Company is almost debt free."]
- − ["The company has delivered a poor profit growth of 1.8% over past five years.", "Though the company is reporting repeated profits, it is not paying out dividend"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.